Article summary
This open-label pilot feasibility study (n=9) gave escalating oral doses of ibogaine, up to 400 mg, to adults with moderate to severe alcohol use disorder under continuous hospital monitoring. QTc changes occurred in five patients and mild to moderate adverse effects were common, and although most reported drinking less, only five completed the study.
Continue to the original publication for the complete article.